Blueprint Medicines Corporation / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €1.57B +22.0% €874.53M +44.9% 55.8% +0.088 pp N/A N/A
    (estimated) €1.29B +21.9% €603.46M +71.2% 46.9% +0.14 pp N/A N/A
    (estimated) €1.05B +26.5% €352.44M +110.6% 33.4% +0.13 pp N/A N/A
    (estimated) €833.97M +35.4% €167.35M -667.1% 20.1% +0.25 pp N/A N/A
    (estimated) €615.83M +41.9% -€29.51M -48.4% -4.8% +0.084 pp N/A N/A
    €434.00M +104.0% -€57.22M -86.8% -13.2% +1.9 pp -€160.32M -55.3% -36.9% +1.3 pp
    €212.71M +22.2% -€432.43M -9.1% -203.3% +0.70 pp -€358.91M -14.7% -168.7% +0.73 pp
    €174.03M +13.3% -€475.53M -13.4% -273.2% +0.84 pp -€420.81M +1,218.7% -241.8% -2.2 pp
    €153.60M -77.3% -€549.37M -305.2% -357.7% -4.0 pp -€31.91M -109.6% -20.8% -0.70 pp
    €677.02M +1,093.4% €267.73M -195.5% 39.5% +5.3 pp €332.82M -247.8% 49.2% +4.5 pp
    €56.73M +49.4% -€280.37M +38.9% -494.2% +0.37 pp -€225.18M +62.6% -396.9% -0.32 pp
    €37.97M +107.8% -€201.84M +59.8% -531.5% +1.6 pp -€138.46M +55.6% -364.6% +1.2 pp
    €18.28M -22.9% -€126.34M +104.3% -691.3% -4.3 pp -€89.01M +370.9% -487.0% -4.1 pp
    €23.69M +143.6% -€61.83M +37.4% -261.0% +2.0 pp -€18.90M -17.3% -79.8% +1.6 pp
    €9.72M +∞% -€45.01M +31.0% -462.9% -4.6 pp -€22.85M -22.8% -235.0% -2.4 pp
    €0.00 +NaN% -€34.36M +92.6% N/A -€29.60M +84.9% N/A
    €0.00 -€17.84M N/A -€16.01M N/A

    Notifications